Last month, C4 Therapeutics dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, combined with ...
Experts in the management of multiple myeloma consider promising developments for the future of relapsed/refractory treatment, with special consideration to bispecific antibodies and CAR (chimeric ...
Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time. C. Ola Landgren, MD, PhD: Hello and ...
The FDA has granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for relapsed or refractory multiple myeloma (MM) after at least four prior lines of therapy, including a proteasome ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma ...
Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study In the training set (N = 7,072), at a median ...
AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 30, 2026 /PRNewswire/ -- Insilico Medicine ...
Risk factors such as LDH, del(17p), t(4;14), and 1q gain/amp(1q1), that predict overall survival and progression-free survival, were used to develop and validate an additive risk score for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results